Baidu
map

JAMA Intern Med:静脉血栓形成诊治十大要点:有危险因素者建议抗凝3个月

2017-06-09 钟巧青 高磊 中国循环杂志

JAMA内科医学杂志发文,提出应对有诱发因素的VTE患者检测其血栓形成倾向,以下是该文的十大要点。

JAMA内科医学杂志发文,提出应对有诱发因素的VTE患者检测其血栓形成倾向,以下是该文的十大要点。

1 在美国,每年有约30~60万患者受静脉血栓形成(VTE)这一疾病的影响。

2 VTE复发风险的评估最好是基于初发VTE是否有诱发因素,而不是遗传性血栓形成倾向的测试结果。

3 大多数发生VTE的患者都有近期手术史、制动、外伤、或患癌症,或同期使用激素类药物等,这些都被认为是VTE的诱发因素。

4  对于首次发生VTE且有诱发因素的患者,指南推荐应用仅3个月的抗凝药物。延长使用抗凝药物可能会增加出血的风险,且这样的出血风险更甚于再发VTE。

5 无明显上述诱发因素的VTE则需要更长时间的抗凝,因为这类患者再发VTE的风险高于延长抗凝药物导致的出血风险。

6 在急性血栓形成或正应用抗凝药物的过程中做血栓形成倾向检测常常会得出一些不确切的结果,如假阳性等。例如,天然的抗凝成分如蛋白质C/S和抗凝血酶在急性血栓性事件时常常被大量消耗,而且这些物质的水平在抗凝治疗时也是降低的。

7 最近的一项研究表明,有55%的患者在发生有诱发因素的VTE时接受了不恰当的血栓形成倾向检测。

8 对初次发生不明原因VTE的年轻(<45岁)患者,或VTE发生在临床罕见的部位时,则做该项测试可能有益。

9 对于无诱因VTE的年轻患者,或在罕见部位发生VTE,或动脉栓塞,或妊娠肥胖,则检测抗磷脂抗体、JAK2基因突变以及阵发性夜间血红蛋白尿,可能是有益的。

10 在VTE患者中应用CT等手段进行癌症筛查并无意义,仅推荐常规的、适龄的癌症筛查。

原始出处:

Arjun Gupta, Ravi Sarode, Srikanth Nagalla. Thrombophilia Testing in Provoked Venous Thromboembolism: A Teachable Moment. JAMA Intern Med. Published online June 5, 2017. doi:10.1001/jamainternmed.2017.1815

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1697475, encodeId=c10f169e4752a, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed May 09 07:42:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955293, encodeId=6e0e1955293f3, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Wed Sep 20 12:42:00 CST 2017, time=2017-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483252, encodeId=c47a1483252fa, content=<a href='/topic/show?id=c82e991e71b' target=_blank style='color:#2F92EE;'>#静脉血栓形成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99177, encryptionId=c82e991e71b, topicName=静脉血栓形成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d387907505, createdName=ms5187542471278033, createdTime=Sun Jun 11 03:42:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607629, encodeId=c0d6160e629e3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jun 11 03:42:00 CST 2017, time=2017-06-11, status=1, ipAttribution=)]
    2018-05-09 fusion
  2. [GetPortalCommentsPageByObjectIdResponse(id=1697475, encodeId=c10f169e4752a, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed May 09 07:42:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955293, encodeId=6e0e1955293f3, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Wed Sep 20 12:42:00 CST 2017, time=2017-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483252, encodeId=c47a1483252fa, content=<a href='/topic/show?id=c82e991e71b' target=_blank style='color:#2F92EE;'>#静脉血栓形成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99177, encryptionId=c82e991e71b, topicName=静脉血栓形成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d387907505, createdName=ms5187542471278033, createdTime=Sun Jun 11 03:42:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607629, encodeId=c0d6160e629e3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jun 11 03:42:00 CST 2017, time=2017-06-11, status=1, ipAttribution=)]
    2017-09-20 xue8602
  3. [GetPortalCommentsPageByObjectIdResponse(id=1697475, encodeId=c10f169e4752a, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed May 09 07:42:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955293, encodeId=6e0e1955293f3, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Wed Sep 20 12:42:00 CST 2017, time=2017-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483252, encodeId=c47a1483252fa, content=<a href='/topic/show?id=c82e991e71b' target=_blank style='color:#2F92EE;'>#静脉血栓形成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99177, encryptionId=c82e991e71b, topicName=静脉血栓形成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d387907505, createdName=ms5187542471278033, createdTime=Sun Jun 11 03:42:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607629, encodeId=c0d6160e629e3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jun 11 03:42:00 CST 2017, time=2017-06-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1697475, encodeId=c10f169e4752a, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed May 09 07:42:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955293, encodeId=6e0e1955293f3, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Wed Sep 20 12:42:00 CST 2017, time=2017-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483252, encodeId=c47a1483252fa, content=<a href='/topic/show?id=c82e991e71b' target=_blank style='color:#2F92EE;'>#静脉血栓形成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99177, encryptionId=c82e991e71b, topicName=静脉血栓形成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d387907505, createdName=ms5187542471278033, createdTime=Sun Jun 11 03:42:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607629, encodeId=c0d6160e629e3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jun 11 03:42:00 CST 2017, time=2017-06-11, status=1, ipAttribution=)]

相关资讯

Lancet Haematol:不明原因静脉血栓栓塞:利伐沙班or华法林?

2017年5月,发表在《Lancet Haematol》的一项由丹麦和英国科学家进行的倾向匹配国内队列研究,考察了利伐沙班和华法林在原因不明静脉血栓栓塞患者中的有效性和安全性。

Eur Heart J:更多的证据肯定了他汀类预防静脉血栓的疗效!

莱斯特大学和布里斯托尔大学的研究人员已经发现进一步的证据表明,他汀类可以“显著降低”身体某些部位血液凝固的发生。

Eur Heart J:他汀类药物可预防静脉血栓

莱斯特大学和布里斯托尔大学的研究人员已经发现进一步的证据表明,他汀类药物可以“显著降低”身体某些部位血液凝固的发生。

NEJM:利伐沙班对长期静脉血栓的预防效果优于阿司匹林

对于需持续抗凝的静脉血栓患者,10mg(预防剂量)和20mg(治疗剂量)的利伐沙班表现出了较好的抗血栓效果且不会增加出血风险。

J Thromb Haemost:身高越高越容易发生静脉血栓栓塞吗?

由此可见,身高越高,欧洲血统的成年人患VTE的风险就越高。这种相关性可能的解释,包括更高的人可能有更大的静脉表面积,更多的静脉瓣膜,或更大的静水压力,但仍需要进一步探讨。

Int J Clin Pharm:术后患者静脉血栓栓塞的风险因素

手术后,患者处于较高的进展静脉血栓栓塞症的风险,临床表现为深静脉血栓(DVT)或肺栓塞(PE)。2017年4月,发表在《Int J Clin Pharm.》的一项病例对照研究表明,多药治疗和血液产品是术后患者静脉血栓栓塞的风险因素。

Baidu
map
Baidu
map
Baidu
map